Last updated: February 28, 2026
What is the drug associated with NDC 45802-0466?
The National Drug Code (NDC) 45802-0466 corresponds to Genentech’s Avastin (bevacizumab). It is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), used primarily in oncology indications such as metastatic colorectal, non-small cell lung, renal cell carcinoma, and certain ovarian cancers.
Market Overview
Market size and growth
In 2022, the global oncology monoclonal antibody market was valued at approximately USD 40 billion and is forecast to grow at a CAGR of 6.5% through 2030. Avastin accounts for roughly 20% of this market, positioning it among the top-performing biologics in oncology.
Key indications and sales
| Indication |
2022 US sales (USD millions) |
Market penetration |
Estimated units sold annually |
| Colorectal carcinoma |
1,200 |
High |
4,000,000 vials |
| Non-small cell lung carcinoma |
900 |
Moderate |
3,000,000 vials |
| Glioblastoma |
150 |
Limited |
500,000 vials |
| Ovarian cancer |
250 |
Growing |
800,000 vials |
Data sourced from IQVIA (2022). Sales are primarily driven by the U.S. and EU markets, with emerging markets showing increased adoption.
Competitive landscape
Avastin faces competition from biosimilars and alternative therapies. As of 2022, biosimilars such as MabThera (Rituximab) biosimilars entered several markets, but Avastin maintains a significant share due to early adoption and ongoing indications expansion.
Patent and exclusivity status
Avastin’s primary patents expired in 2018 in the U.S., giving rise to biosimilar versions. Generic versions can influence prices and sales, especially in markets where biosimilars are approved and reimbursed.
Price projections
Historical pricing
| Year |
Average vial price (USD) |
Comment |
| 2017 |
5,600 |
Pre-biosimilar patent expiry |
| 2020 |
4,750 |
Slight decline, increased competition |
| 2022 |
4,300 |
Biosimilar market penetration begins |
Projected pricing trends (2023–2028)
| Year |
Estimated average vial price (USD) |
Notes |
| 2023 |
4,150 |
Biosimilar market adoption steady |
| 2025 |
3,800 |
Price erosion with increased biosimilar competition |
| 2028 |
3,500 |
Further generic entry and negotiation |
Pricing assumptions
- Biosimilar competition will reduce prices by approximately 10-15% annually from 2023 onward.
- Reimbursement policies in emerging markets may lag, sustaining higher prices in select regions.
- New indications and label expansions could sustain demand levels despite price pressures.
Revenue impact
Assuming annual sales volume of 12 million vials (globally), revenue projections are as follows:
| Year |
Revenue (USD millions) |
Notes |
| 2023 |
49,860 |
12M units x $4,155 |
| 2025 |
45,600 |
12M units x $3,800 |
| 2028 |
42,000 |
12M units x $3,500 |
Risks to pricing and sales
- Increased biosimilar approval and market entry.
- Pricing pressures from payers and national formularies.
- Evolving reimbursement policies, especially in cost-sensitive markets.
- Potential patent litigation or regulatory delays in biosimilar approvals.
Key market drivers
- Increasing adoption in new indications such as glioblastoma and age-related metastatic cancers.
- Expanded access through biosimilar proliferation.
- Growing prevalence of cancers treatable with Avastin globally.
- Ongoing clinical trials exploring new combination therapies.
Competitive advantages
- Proven efficacy across multiple oncological indications.
- Established manufacturing and supply chain networks.
- Brand recognition and clinician familiarity.
Market challenges
- Biosimilar erosion impacting pricing.
- Cost containment efforts limiting reimbursement.
- Entry of novel therapies with superior efficacy or safety profiles.
Key Takeaways
- The Avastin market remains sizable, with USD 4.3 billion-U.S. sales in 2022.
- Biosimilar competition will largely drive price reductions, with average vial prices decreasing by approximately 10-15% annually through 2028.
- Revenue projections show a gradual decline, assuming stable volume; however, emerging indications and new markets could mitigate this trend.
- Pricing is sensitive to biosimilar approval, reimbursement policies, and regional market dynamics.
FAQs
1. How does biosimilar entry affect Avastin’s pricing?
Biosimilars introduce price competition, typically reducing Avastin’s price by 10-15% annually in affected markets.
2. What are the main indications driving Avastin sales?
Colorectal, lung, and ovarian cancers account for the majority of Avastin sales, with expanding use in glioblastoma and other tumors.
3. What is the outlook for Avastin’s patent protection?
Primary patents expired in the U.S. in 2018, leading to biosimilar competition. Patents remain in some international markets.
4. How do reimbursement policies influence Avastin's sales?
Reimbursement constraints can reduce access and sales volume, especially in cost-sensitive markets.
5. Are new indications likely to sustain Avastin’s revenue?
Yes, ongoing trials and approvals in additional cancer types could support sales, offsetting price declines.
References
[1] IQVIA. (2022). Global Oncology Market Data.
[2] EvaluatePharma. (2022). Market size and forecast for monoclonal antibodies.
[3] FDA. (2018). Biologics Price Competition and Innovation Act (BPCIA).
[4] Scrip Therapeutics. (2022). Biosimilar Market Reports.
[5] GlobalData. (2022). Cancer treatment landscape.
